Editorial Commentary: Platelet-Rich Plasma Reduces Retear Rates Following Rotator Cuff Repair but Does Not Improve Clinical Outcomes

Malavolta, 2011, Randomized controlled clinical trials in orthopedics: Difficulties and limitations, Rev Brasil Ortop, 46, 452, 10.1590/S0102-36162011000400018 Deaton, 2018, Understanding and misunderstanding randomized controlled trials, Soc Sci Med, 210, 2, 10.1016/j.socscimed.2017.12.005 Souza, 2020, Research methodologic quality varies significantly by subspecialty: An analysis of AAOS meeting abstracts, J Clin Orthop Trauma, 15, 37, 10.1016/j.jcot.2020.11.001 Matar, 2019, Overview of randomized controlled trials in orthopaedic research: Search for significant findings, Eur J Orthop Surg Traumatol, 29, 1163, 10.1007/s00590-019-02436-0 Sheean, 2021, Platelet-rich plasma: Fundamentals and clinical applications, Arthroscopy, 37, 2732, 10.1016/j.arthro.2021.07.003 Zhang, 2022, Injection of leukocyte-poor platelet-rich plasma for moderate-to-large rotator cuff tears do not improve clinical outcomes but reduce retear rates and fatty infiltration: A prospective single-blinded randomized study, Arthroscopy, 38, 2381, 10.1016/j.arthro.2022.02.007 Villaarreal-Villaarreal, 2021, Double-row rotator cuff repair enhanced with platelet-rich therapy reduces retear rate: A systematic review and meta-analysis of randomized controlled trials, Arthroscopy, 37, 1937, 10.1016/j.arthro.2020.12.191 Malavolta, 2018, Clinical and structural evaluations of rotator cuff repair with and without added platelet-rich plasma at 5-year follow-up: A prospective randomized study, Am J Sports Med, 46, 3134, 10.1177/0363546518795895 Randelli, 2022, Platelet-rich plasma in arthroscopic rotator cuff repair: Clinical and radiological results of a prospective randomized trial study at 10-year follow-up, Arthroscopy, 38, 51, 10.1016/j.arthro.2021.05.017 Eliasberg, 2021, Complications following biologic therapeutic injections: a multicenter case series, Arthroscopy, 37, 2600, 10.1016/j.arthro.2021.03.065 Freedman, 2021, Editorial Commentary: Risks of biologic therapies in sports medicine: Landmines on the road to the holy grail, Arthroscopy, 37, 2606, 10.1016/j.arthro.2021.06.003